Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1968 2
1969 3
1970 1
1971 1
1973 2
1974 5
1975 1
1976 4
1977 5
1978 1
1979 2
1980 4
1981 9
1982 11
1983 5
1984 4
1985 4
1986 6
1987 5
1988 16
1989 8
1990 14
1991 12
1992 18
1993 10
1994 14
1995 62
1996 159
1997 170
1998 252
1999 287
2000 268
2001 252
2002 319
2003 344
2004 339
2005 388
2006 400
2007 408
2008 489
2009 496
2010 604
2011 860
2012 974
2013 792
2014 698
2015 824
2016 709
2017 669
2018 802
2019 319
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

11,053 results
Results by year
Filters applied: . Clear all
Page 1
Doravirine: a review
Colombier MA and Molina JM. Curr Opin HIV AIDS 2018 - Review. PMID 29794817
The main features of DOR are reviewed in this report including its antiviral activity, genetic barrier to resistance, safety, once-daily dosing and coformulation in a single tablet with tenofovir disoproxil fumarate and lamivudine. ...DOR has shown excellent antiviral activity in treatment-naïve patients, a better safety profile than EFV and a low potential for drug-drug interactions....
The main features of DOR are reviewed in this report including its antiviral activity, genetic barrier to resistance, safety, once-da …
Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation.
El Helou G and Razonable RR. Expert Opin Drug Saf 2019 - Review. PMID 31478398
Areas covered: This review discusses the safety profiles of currently available and emerging antiviral drugs and the other strategies for HCMV prevention and treatment after transplantation. ...In choosing the antiviral medication to use, it is important to consider these safety profiles in addition to overall efficacy. ...
Areas covered: This review discusses the safety profiles of currently available and emerging antiviral drugs and the other strategies …
Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.
Wilhelmus KR. Cochrane Database Syst Rev 2015 - Review. PMID 25879115 Free PMC article.
Compared to topical antiviral monotherapy, the combination of an antiviral with either interferon or debridement had inconsistent effects on expediting healing and improving outcome. ...The addition of interferon to a nucleoside antiviral agent and the combination of debridement with antiviral treatment need to be further assessed to substantiate any possible advantage in healing....
Compared to topical antiviral monotherapy, the combination of an antiviral with either interferon or debridement had inconsist …
Management of chronic viral hepatitis in the hematological patient
Nicolini LA, et al. Expert Rev Anti Infect Ther 2018 - Review. PMID 29415584
With regard to HCV, the new direct-acting antiviral agents have been safely administered in the hematological setting. Their use as first-line single treatment in indolent lymphomas, and combined with chemotherapy in aggressive ones, should be considered. ...
With regard to HCV, the new direct-acting antiviral agents have been safely administered in the hematological setting. Their use as f …
Direct-acting antiviral treatment of acute hepatitis C virus infections.
Misra S, et al. Expert Rev Anti Infect Ther 2018 - Review. PMID 30067402
Treating acute hepatitis C virus (AHCV) with direct-acting antiviral agents in persons who inject drugs, HIV-positive men who have sex with men, and patients who acquire HCV nosocomially can contribute to the elimination of disease globally, preclude the morbidity and mortality of chronic disease, and prevent further transmission. ...
Treating acute hepatitis C virus (AHCV) with direct-acting antiviral agents in persons who inject drugs, HIV-positive men who have se …
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation
Struble K, et al. Hepatology 2018. PMID 29059462
Approval was based on an acceptable safety profile and high sustained virological response rates 12 weeks after the end of treatment (SVR12) in two phase 3 clinical trials in subjects previously treated with a direct-acting antiviral (DAA) regimen. ...
Approval was based on an acceptable safety profile and high sustained virological response rates 12 weeks after the end of treatment (SVR12) …
Antiviral agents.
Keating MR. Mayo Clin Proc 1992 - Review. PMID 1347578
In recent years, the antiviral armamentarium has expanded considerably. Currently available agents are virustatic, inhibiting specific steps in the process of viral replication. ...With the expanded use of and indications for antiviral therapy, clinically significant resistance to these agents has been encountered with increasing frequency....
In recent years, the antiviral armamentarium has expanded considerably. Currently available agents are virustatic, inhibiting specifi …
11,053 results
Jump to page
Feedback